Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

AstraZeneca Announced Camizestrant Significantly Improved Progression-free Survival vs. Faslodex in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer

By Charles Gross
Today, 4:27 PM
Positive high-level results from the SERENA-2 Phase II trial showed that AstraZeneca's next-generation oral selective estrogen receptor degrader (ngSERD) camizestrant met the primary endpoint of demonstrating a statistically significant and clinically meaningful progression-free survival (PFS) benefit at both 75mg and 150mg dose levels versus Faslodex (fulvestrant) 500mg in post-menopausal patient

AZN

Read More
3 minute read

US Stock Futures Lower Following Friday’s Rally; Tesla In Focus

By Lisa Levin
Today, 4:27 PM
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the three major indices recorded their best week since June, with the S&P 500 and Dow adding 4.7% and 4.9%, respectively last week.

AVEO